Bicycletx Limited

6 trials 1 recruiting Commercial sponsor

Filter these 6 trials by condition, phase, country and more.

Open in Search →

6 Registered trials

1 Recruiting

4 Completed trials

18 Countries active

9 Unique IMPs

100% Results reported

Phase II/III

Phase II

Phase I (FiH)

Phase II/III: 2 Phase II: 2 Phase I (FiH): 2

100%

4 of 4 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Transitional cell carcinoma 2 Breast cancer 1 Non-small cell lung cancer stage IV 1 Non-small cell lung cancer metastatic 1 Hormone receptor positive HER2 negative breast cancer 1 Triple negative breast cancer 1 Breast cancer metastatic 1

Top IMPs

ZELENECTIDE PEVEDOTIN 4 BT8009 1 MONOMETHYL AURISTATIN E LINKED TO A SARCOSINE DECAMER WITH A BETA-ALANINE N-TERMINUS AND BCY9594 VIA A CLEAVABLE LINKER 1

All trials

6 total

Study BT8009-230 in Subjects with Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2) Not authorised

2023-504231-41-00 Phase II/III 1 country BT8009
Study BT8009-230 in Subjects with Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2) Recruiting

2023-504231-41-01 Phase II/III 18 countries ZELENECTIDE PEVEDOTIN
Zelenectide Pevedotin in NECTIN4 Amplified Advanced or Metastatic Non-small Cell Lung Cancer Ended

2025-521115-40-00 Phase II 4 countries ZELENECTIDE PEVEDOTIN
Study of Zelenectide Pevedotin in Participants with Advanced Breast Cancer Ended

2024-517868-33-00 Phase II 4 countries ZELENECTIDE PEVEDOTIN
Study BT5528-100 in Patients with Advanced Solid Tumors Associated with EphA2 Expression Ended

2024-510655-36-00 Phase I (FiH) 2 countries MONOMETHYL AURISTATIN E LINKED TO A SARCOSINE DECAMER WITH A BETA-ALANINE N-TERM…
Study BT8009-100 in Patients with Nectin-4 Expressing Advanced Malignancies. Ended

2023-509781-37-00 Phase I (FiH) 3 countries ZELENECTIDE PEVEDOTIN

Showing 1–6 of 6 trials

← All sponsors A–Z